Frédéric Y. Bois

Q: What Schools Are Affiliated With Frédéric Y. Bois

Frédéric Y. Bois is affiliated with the following schools: University of California, Berkeley, Université Paris Cité, University of Technology of Compiègne

Frédéric Y. Bois's AcademicInfluence.com Rankings

Frédéric Y. Bois

Medical

#2322

World Rank

#2739

Historical Rank

Toxicology

#52

World Rank

#56

Historical Rank

medical Degrees

Frédéric Y. Bois

Biology

#8642

World Rank

#11750

Historical Rank

Bioinformatics

#181

World Rank

#183

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Frédéric Y. Bois's Degrees

PhD Toxicology Université Paris Cité

Why Is Frédéric Y. Bois Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Frédéric Yves Bois is a French biological scientist working in toxicology and bioinformatics. He is currently Senior Scientific Advisor at Simcyp, a Certara-owned company. Biography Frédéric Bois was born in Limoges, France, in 1958. He obtained his Pharm.D. from the and his Ph.D. from the University of Metz . Most of his Ph.D. thesis, on the use of physiologically based pharmacokinetic models and stochastic carcinogenesis models for risk assessment, was developed at the Harvard University Energy and Environmental Policy Center . His post-doctoral research was performed at UCSF and UC Berkeley School of Public Health. He then held joint appointments at the California Environmental Protection Agency and the Lawrence Berkeley National Laboratory . Upon his return to France he worked at INSERM until 1998. He was Research Director at the INERIS research lab from 1999 to 2019. From 2009 to 2015 he was also incumbent of Chair of Mathematical Modelling for Systems Toxicology of the . He is now Senior Scientific Advisor in the Simcyp division of the Certara Company. He is married to Nicole Cancré and they have four children: Pauline, Jules, Eugène and Camille.

(See a Problem?)

Frédéric Y. Bois's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 (2011) (536)
Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions (1996) (361)
Adverse outcome pathways: opportunities, limitations and open questions (2017) (245)
Adverse outcome pathways: opportunities, limitations and open questions (2017) (245)
Metabolomics in toxicology and preclinical research. (2013) (174)
Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. (2013) (161)
Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. (2013) (161)
PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. (2010) (159)
Integrated Testing Strategies (ITS) for safety assessment. (2015) (144)
Statistical issues in toxicokinetic modeling: a bayesian perspective. (2000) (140)
Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. (2007) (131)
Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. (2013) (130)
Joint modeling of survival and longitudinal non‐survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group (2015) (128)
An overview of transcriptional regulation in response to toxicological insult (2012) (123)
PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. (2014) (120)
Bayesian-Optimal Design via Interacting Particle Systems (2006) (114)
GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models (2009) (113)
Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. (2008) (110)
A Review of the Evidence that Ochratoxin A Is an Nrf2 Inhibitor: Implications for Nephrotoxicity and Renal Carcinogenicity (2014) (106)
Addressing Human Variability in Next-Generation Human Health Risk Assessments of Environmental Chemicals (2012) (103)
Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. (2000) (101)
Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. (2015) (99)
Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. (2015) (99)
Population toxicokinetics of benzene. (1996) (96)
Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. (1990) (95)
Population toxicokinetics of tetrachloroethylene (1996) (92)
Development of a physiologically based kinetic model for 99m-Technetium-labelled carbon nanoparticles inhaled by humans (2009) (80)
MCSim: A Monte Carlo Simulation Program (1997) (79)
Toxicokinetic models and related tools in environmental risk assessment of chemicals. (2017) (76)
The Next Generation of Risk Assessment Multi-Year Study—Highlights of Findings, Applications to Risk Assessment, and Future Directions (2016) (75)
Meeting Report: Moving Upstream—Evaluating Adverse Upstream End Points for Improved Risk Assessment and Decision-Making (2008) (74)
Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda (2007) (74)
Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes. (2011) (72)
Bioequivalence: Performance of Several Measures of Rate of Absorption (1994) (72)
Ab initio chemical safety assessment: A workflow based on exposure considerations and non-animal methods (2017) (70)
Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications. (1991) (66)
Delineation of the Key Aspects in the Regulation of Epithelial Monolayer Formation (2013) (65)
Interspecies extrapolation: a reexamination of acute toxicity data. (1992) (62)
Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. (2000) (60)
Dynamic modeling of bacteria in a pilot drinking-water distribution system (1997) (59)
Comparison of three physiologically based pharmacokinetic models of benzene disposition. (1991) (58)
Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. (2012) (58)
Structure and parameterization of pharmacokinetic models: their impact on model predictions. (1992) (55)
Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl. (1995) (53)
Bacterial inoculum density and probability of para-nitrophenol biodegradability test response. (1995) (51)
Analysis of PBPK Models for Risk Characterization (1999) (47)
Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model (2012) (47)
Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling (2018) (46)
Possible risk of endometriosis for Seveso, Italy, residents: an assessment of exposure to dioxin. (1994) (46)
Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism. (1991) (45)
Oxidative stress induced by potassium bromate exposure results in altered tight junction protein expression in renal proximal tubule cells (2012) (45)
Generic physiologically-based toxicokinetic modelling for fish: Integration of environmental factors and species variability. (2019) (44)
Evaluating health risks from occupational exposure to pesticides and the regulatory response. (1994) (44)
Optimal design for a study of butadiene toxicokinetics in humans. (1999) (44)
Absorption Rate Vs. Exposure: Which Is More Useful for Bioequivalence Testing? (1996) (44)
Lumping in Pharmacokinetics (2005) (44)
Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: empirical results and comparisons with previous studies. (2007) (42)
Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study. (2015) (41)
Physiologically based modelling and prediction of drug interactions. (2010) (41)
Applications of population approaches in toxicology. (2001) (39)
An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model. (1992) (37)
Influence of physicochemical parameters on the microtox test response (1986) (37)
Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. (2013) (36)
Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells (2014) (36)
In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments. (2015) (35)
Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing. (2015) (35)
Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing. (2015) (35)
Low-dose metabolism of benzene in humans: science and obfuscation. (2013) (34)
Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: global sensitivity analysis for experimental design issues. (2007) (33)
Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects (2001) (32)
Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats. (2014) (32)
Optimization issues in physiological toxicokinetic modeling: a case study with benzene. (1993) (32)
Bioequivalence: Performance of Several Measures of Extent of Absorption (2004) (31)
Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems. (2015) (31)
Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions (2012) (31)
Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq (2018) (30)
Application of three approaches for quantitative AOP development to renal toxicity (2019) (30)
Application of three approaches for quantitative AOP development to renal toxicity (2019) (30)
Integration of Omics Data and Systems Biology Modeling: Effect of Cyclosporine A on the Nrf2 Pathway in Human Renal Kidneys Cells (2013) (27)
Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results. (1994) (27)
Interspecies extrapolation of physiological pharmacokinetic parameter distributions. (1996) (27)
Environmental benzene exposure assessment for parent-child pairs in Rouen, France. (2001) (27)
Interleukin-19 as a translational indicator of renal injury (2014) (27)
Quantitative in vitro to in vivo extrapolation of tissues toxicity. (2015) (26)
Evidence for a role of claudin 2 as a proximal tubular stress responsive paracellular water channel. (2014) (26)
Multiscale modelling approaches for assessing cosmetic ingredients safety. (2017) (25)
Advancing human health risk assessment (2019) (25)
Investigation of omeprazole and phenacetin first‐pass metabolism in humans using a microscale bioreactor and pharmacokinetic models (2015) (25)
Pentachlorophenol Carcinogenicity: Extrapolation of Risk from Mice to Humans (1993) (24)
The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods (2020) (24)
Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing. (2015) (24)
A Bayesian compartmental model for the evaluation of 1,3‐butadiene metabolism (2003) (24)
Multiple regression analysis of toxic interactions: Application to the microtox test and general comments (1986) (23)
Development of a molecular method to detect and quantify Aphanomyces euteiches in soil. (2007) (23)
Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models (2020) (23)
Benzene toxicokinetics in humans: exposure of bone marrow to metabolites. (1994) (23)
Phleum pratense pollen starch granules induce humoral and cell‐mediated immune responses in a rat model of allergy (2003) (22)
Improving global feature detectabilities through scan range splitting for untargeted metabolomics by high-performance liquid chromatography-Orbitrap mass spectrometry. (2016) (22)
The Application of a Bayesian Approach to the Analysis of a Complex, Mechanistically Based Model (2007) (21)
Assessment of Pentachlorophenol Exposure in Humans using the Clearance Concept (1992) (21)
Genetic and dietary factors affecting human metabolism of 1,3-butadiene. (2001) (21)
Statistical and Regulatory Considerations for Multiple Measures in Bioequivalence Testing (1995) (20)
Evaluating Standards for Protecting Aquatic Life in Washington ' s Surface Water Quality Standards Temperature Criteria Draft Discussion Paper and Literature Summary (2000) (19)
Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging. (2006) (19)
A Mechanistic Modeling Framework for Predicting Metabolic Interactions in Complex Mixtures (2011) (18)
Investigation of acetaminophen toxicity in HepG2/C3a microscale cultures using a system biology model of glutathione depletion (2015) (18)
A group sequential approach to crossover trials for average bioequivalence. (1997) (17)
Application of clearance concepts to the assessment of exposure to lead in drinking water. (1989) (17)
Inter-laboratory study of human in vitro toxicogenomics-based tests as alternative methods for evaluating chemical carcinogenicity: a bioinformatics perspective (2016) (16)
Placental transfer of xenobiotics in pregnancy physiologically-based pharmacokinetic models: Structure and data (2019) (16)
Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure. (2014) (16)
Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases (2018) (16)
A Computational Model to Predict Rat Ovarian Steroid Secretion from In Vitro Experiments with Endocrine Disruptors (2013) (16)
Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases (2018) (16)
Intratracheal Instillation of Cytoplasmic Granules from Phleum pratense Pollen Induces IgE- and Cell-Mediated Responses in the Brown Norway Rat (2004) (14)
Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim (2019) (14)
Analysis of Time-Series Gene Expression Data to Explore Mechanisms of Chemical-Induced Hepatic Steatosis Toxicity (2018) (14)
Revisiting the population toxicokinetics of tetrachloroethylene (2006) (13)
A parametric approach to population bioequivalence. (1997) (13)
Modeling Pharmacokinetics. (2016) (12)
Prediction of maternal and foetal exposures to perfluoroalkyl compounds in a Spanish birth cohort using toxicokinetic modelling. (2019) (12)
Benzene Toxicokinetics in Humans-Bone Marrow Exposure to Metabolites (1994) (11)
Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogs. (2020) (11)
The Use of Pharmacokinetic Models in the Determination of Risks for Regulatory Purposes (1989) (11)
Probabilistic Generation of Random Networks Taking into Account Information on Motifs Occurrence (2013) (10)
Sequential Updating of a New Dynamic Pharmacokinetic Model for Caffeine in Premature Neonates (2007) (10)
Responses to discussants of ‘Joint modeling of survival and longitudinal non‐survival data: current methods and issues. report of the DIA Bayesian joint modeling working group’ (2015) (10)
DECREASE IN OVALBUMIN-INDUCED PULMONARY ALLERGIC RESPONSE BY BENZALDEHYDE BUT NOT ACETALDEHYDE EXPOSURE IN A GUINEA PIG MODEL (2002) (10)
Nephron Toxicity Profiling via Untargeted Metabolome Analysis Employing a High Performance Liquid Chromatography-Mass Spectrometry-based Experimental and Computational Pipeline* (2015) (10)
High-Throughput Analysis of Ovarian Cycle Disruption by Mixtures of Aromatase Inhibitors (2016) (10)
Extrapolating In Vitro Results to Predict Human Toxicity (2014) (10)
Pharmacokinetic-pharmacodynamic models for categorical toxicity data. (2005) (9)
Application of Evidence-Based Methods to Construct Mechanism-Driven Chemical Assessment Frameworks (2022) (9)
A read-across case study on chronic toxicity of branched carboxylic acids (1): Integration of mechanistic evidence from new approach methodologies (NAMs) to explore a common mode of action. (2021) (9)
Sensitivity analysis of a new model of carcinogenesis. (1991) (9)
Comprehensive summary--Predict-IV: A systems toxicology approach to improve pharmaceutical drug safety testing. (2015) (8)
Choice of student's t- or Wilcoxon-based confidence intervals for assessment of average bioequivalence. (1997) (8)
Use of a Chemical Probe to Increase Safety for Human Volunteers in Toxicokinetic Studies (2005) (8)
Occupational Exposure to Cobalt: A Population Toxicokinetic Modeling Approach Validated by Field Results Challenges the Biological Exposure Index for Urinary Cobalt (2009) (7)
Identifiability of sorption parameters in stirred flow-through reactor experiments and their identification with a Bayesian approach. (2016) (7)
Well-tempered MCMC simulations for population pharmacokinetic models (2020) (7)
Quantitative AOP based teratogenicity prediction for mixtures of azole fungicides (2019) (7)
Population effects and variability. (2012) (6)
A generic PBTK model implemented in the MCRA platform: Predictive performance and uses in risk assessment of chemicals. (2020) (6)
Uncertainty Analysis: The Bayesian Approach (2006) (6)
Experimental models in nanotoxicology (2011) (6)
Bayesian inference. (2013) (5)
Pharmacokinetic concepts in assessing intake of pentachlorophenol by rats after exposure through drinking water. (1992) (5)
Propylene glycol monomethyl ether. A three-generation study of isomer β effects on reproductive and developmental parameters in rats (2005) (5)
Synergism in carcinogenesis. (1985) (5)
Optimal pollution control strategies in the presence of interacting toxicants (1988) (5)
Considerations in the Attainment of Steady State: Aggregate vs. Individual Assessment (1998) (5)
Computational pharmacokinetics at a crossroads (2013) (4)
Population-Based Pharmacokinetic Modeling and Simulation (2012) (4)
Translational Biomarkers, In Vitro and In Vivo (2014) (4)
Persistence of Epigenomic Effects After Recovery From Repeated Treatment With Two Nephrocarcinogens (2018) (4)
Mid-gestation low-dose LPS administration results in female-specific excessive weight gain upon a western style diet in mouse offspring (2020) (4)
Revisiting the population toxicokinetics of tetrachloroethylene (2006) (4)
An Approximate Method for Population Toxicokinetic Analysis With Aggregated Data (2007) (4)
Opinion of the Committee for Prevention and Precaution about the Precautionary Principle (2006) (4)
Multistate models of developmental toxicity: Application to valproic acid-induced malformations in the zebrafish embryo. (2021) (3)
Quantifying heterogeneity in exposure–risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures (2008) (3)
SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp® simulator (2022) (3)
Nanotoxicology: Role of Physical and Chemical Characterization and Related In Vitro , In Vivo , and In Silico Methods (2017) (3)
The Past, Present, and Future of Chemical Risk Assessment (2014) (3)
OpenRiskNet, an open e-infrastructure to support data sharing, knowledge integration and in silico analysis and modelling in risk assessment (2018) (3)
Adverse outcome pathways: opportunities, limitations and open questions (2017) (3)
Stress Response Pathways (2014) (3)
A Discrete-Event Model of Carcinogenesis (2013) (2)
Synergism in Carcinogenesis. Letters to the Editor. (1986) (2)
Predict-IV project overview (EU grant 202222): non animal-based toxicity profiling by integrating toxico dynamics and biokinetics (2013) (2)
Extension of the isobolographic approach to interactions studies between more than two drugs: illustration with the convulsant interaction between pefloxacin, norfloxacin, and theophylline in rats. (2004) (2)
In Vitro Toxicology Systems : Chapter 1: The Past, Present and Future of Chemical Risk Assessment (2014) (2)
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers (2022) (2)
Transcriptomic mapping of the inter-individual variability of cellular stress response activation in primary human hepatocytes (2021) (2)
“Watching the Detectives” report of the general assembly of the EU project DETECTIVE Brussels, 24–25 November 2015 (2016) (2)
Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials: Comment (1997) (2)
Human liver cell cultivation in a miniaturised 3 D bioreactor system for in vitro studies on hepatic drug toxicity (1)
Analysis of Parametric Uncertainty in Physiological Pharmacokinetic and Multistage Cancer Models (1990) (1)
Lead exposure in children vs adults. (1989) (1)
Structure learning of Bayesian networks involving cyclic structures (2019) (1)
Corrigendum to "Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogs" [Reprod. Toxicol. 93 (2020) 219⬜229]. (2020) (1)
Graph_sampler: a simple tool for fully Bayesian analyses of DAG-models (2015) (1)
Benzene toxicokinetics in humans (1997) (1)
Integration of omics data and systems biology modeling: Response of the NFE2L2 pathway in human renal kidneys cells exposed to cyclosporine A in vitro (2013) (1)
Moving upstream : evaluating adverse upstream end points for improved risk assessment and decision-making (2020) (1)
Ignoring and adding errors do not improve the science. (2013) (1)
In Vitro Toxicology Systems : Chapter 19: Stress Response Pathways (2014) (1)
Stochasticity in Physiologically Based Kinetics Models: Implications for Cancer Risk Assessment (2009) (1)
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms (2021) (1)
Application of a human renal proximal tubule cell line, RPTEC/TERT1, for chemical safety assessment (2014) (1)
New tools for evidence-based risk assessment of chemical mixtures (2014) (1)
Physiological modeling of metabolic interactions (2009) (1)
An integrated modelling approach for in vitro to in vivo extrapolations (2010) (1)
Use of biomonitoring data to improve advanced risk assessment models (2008) (1)
KBrO3 induces oxidative stress and tight junction alterations in proximal tubule cells (2012) (0)
Expression of Both Mrp1 and Mdr1 Genes, Two Members of the ABC Transporter Family, is Modulated by the Estrogenic Environmental Pesticide Methoxychlor (2006) (0)
Corrigendum: Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases (2019) (0)
Graph_sampler: a simple tool for fully Bayesian analyses of DAG-models (2017) (0)
A high-throughput analysis of woman ovarian cycle disruption by mixtures of aromatase inhibitors (2016) (0)
Quantitative Bayesian Network Analyses of Mitochondrial Toxicity (2021) (0)
3D human hepatic organoids for testing Fibrosis, Cholestasis and Phospholipidosis (2016) (0)
Development of an integrated system biology model for predicting mixtures of chemicals: the case of the azole fungicides (2016) (0)
Graph sampler: a C language software for fully Bayesian analyses of Bayesian networks (2015) (0)
Integrating multimedia environmental models and effects models on a common platform for risk assessment (2010) (0)
OpenRiskNet Part I: Development of an open e-infrastructure predictive toxicology and risk assessment (2019) (0)
How to integrate in vitro PK/PD information for toxicity prediction (2020) (0)
Population model describing the epidemiology of waterborne disease (1995) (0)
HUMAN IN VITRO LIVER CELL SYSTEMS (2015) (0)
Physiologically based toxicokinetic models for prediction of complex metabolic interactions between chemical in mixtures (2014) (0)
Investigation of acetaminophen toxicity in HepG2/C3a microscale cultures using a system biology model of glutathione depletion (2015) (0)
PBPK Modeling to Simulate the Fate of Compounds in Living Organisms. (2022) (0)
Benzene toxicokinetics inhumans: exposure of bonemarrowtometabolites (1994) (0)
Statistica l Analysi s of Clewel l et al . PBPK Model of Trichloroethylen e Kinetic s (2019) (0)
NAM-supported read-across: from case studies to regulatory guidance in safety assessment (2019) (0)
Systems biology PBPK modelling of metabolic interactions (2009) (0)
Exploring the quantification of renal adverse outcome pathways (2018) (0)
Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework (2022) (0)
Estimating metabolic rate for butadiene at steady state using a Bayesian physiologically-based pharmacokinetic model (2011) (0)
Generic PBTK model for human (2019) (0)
Intratracheal instillation of starch granules from timoty grass pollen induces an airways allergic reaction in a rat model of allergy (2004) (0)
Integrated testing strategies and decision-making (2008) (0)
Computational chemistry solutions supporting chemical safety assessment: Lessons learned for using in silico approaches (2015) (0)
Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions (2012) (0)
Occupational Exposure to Cobalt: a Population Toxicokinetic Modeling Approach Validated by Field Results Challenges the Bei® for Urinary Cobalt (2014) (0)
Bayesian population toxicokinetic modelling (1997) (0)
A New In Vivo Model to Screen Both Estrogenic and Anti-/Androgenic Compounds (2006) (0)
Application ofClearance Concepts totheAssessment of Exposure toLeadinDrinking Water (1989) (0)
Systems biology tools for quantitative AOPs (2017) (0)
Computational pharmacokinetics at a crossroads (2013) (0)
State of the art in issues of uncertainty and variability for PBPK model applications (2006) (0)
Simulation-based optimal design of experiments (2000) (0)
Integrated Testing Strategies ( ITS ) for Safety Assessment 1 (2014) (0)
P12-061Applied chemical safety assessment case study for repeated dose toxicity integrating non-animal methods (2016) (0)
Quantitative modelling of adverse outcome pathway for risk assessment (2017) (0)
Insights into mechanisms underlying inter-individual susceptibility to Drug-Induced-Liver-Injury (DILI) from data on in vitro exposure, transcriptomics and functionality of cryopreserved human primary hepatocytes: The example of chlorpromazine (2013) (0)
Beyond time-homogeneity for continuous-time multistate Markov models (2022) (0)
Development of a predictive in silico model for mixtures of azole fungicides acting on the skeletal craniofacial AOP (2017) (0)
Assessing the influence of inter-individual variability on the pharmacokinetics of environmental chemicals using PBPK modeling (2010) (0)
Integrating toxicokinetics and toxicodynamics to predict toxic responses in vivo (2013) (0)
Kinetics of pulmonary inflammatory response following exposure to ozone or nitrogen dioxide (2001) (0)
Monocyte activation test ( MAT ) : identification of monographs that recommend rabbit pyrogen test ( RPT ) and bacterial endotoxin test ( BET ) as a kick-off for showing applicability of MAT (2014) (0)
Perinatal health risk assessment using physiology-based models : the case of dioxins (2007) (0)
Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim (2019) (0)
microorganisms detection methods by pcr (2006) (0)
Bayesian aggregation of average data in hierarchical models (2015) (0)
Full-chain and UNcertainty Approaches for Assessing Health Risks in FUture ENvironmental Scenarios (2008) (0)
Corrigendum: Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases (2019) (0)
Integration of transcriptomic, epigenomic, proteomic and metabolomic data for the characterisation of the molecular response of renal epithelial cells to repeat-dose exposure to chemicals in vitro (2014) (0)
The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods (2020) (0)
Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model (2011) (0)
P25-05Transcriptomic and functional alterations during renal epithelial maturation (2012) (0)
Differential effects of consecutive chemical exposure-recovery periods on the physiology and defence mechanisms of renal proximal tubule cells (2016) (0)
In Vitro Toxicology Systems : Chapter 20: Translational Biomarkers, In Vitro and In Vivo (2014) (0)
“Watching the Detectives” report of the general assembly of the EU project DETECTIVE Brussels, 24–25 November 2015 (2016) (0)
The use of transcriptomics to assess stress response pathway and nuclear receptor activation for uncovering mechanisms of chemical induced toxicity (2014) (0)
Oxidative stress induced by potassium bromate exposure results in altered tight junction protein expression in renal proximal tubule cells (2012) (0)
Inter-laboratory study of human in vitro toxicogenomics-based tests as alternative methods for evaluating chemical carcinogenicity: a bioinformatics perspective (2015) (0)
Quantification and relationship of stress and adversity in cellular systems (2017) (0)
An overview of transcriptional regulation in response to toxicological insult (2012) (0)
Exploring the quantification of renal adverse outcome pathways (2018) (0)
Lecture in Session VII : Nanotoxicology In vitro model of inflammatory bowel disease for drug formulation testing and screening (0)
Identification of novel mechanistic biomarkers of nephrotoxicity by proteomics and phosphoproteomics (2015) (0)
Interleukin-19 as a translational indicator of renal injury (2014) (0)
Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq (2018) (0)
Monocyte activation test ( MAT ) : identification of monographs that recommend rabbit pyrogen test ( RPT ) and bacterial endotoxin test ( BET ) as a kick-off for showing applicability of MAT (2014) (0)
Environmental contamination and human health in multi-causal scenarios : the 2-FUN project (2008) (0)

This paper list is powered by the following services:

Other Resources About Frédéric Y. Bois

en.wikipedia.org

What Schools Are Affiliated With Frédéric Y. Bois?

Frédéric Y. Bois is affiliated with the following schools:

Frédéric Y. Bois's Academic­Influence.com Rankings

Frédéric Y. Bois's Degrees

Why Is Frédéric Y. Bois Influential?

Frédéric Y. Bois's Published Works

Published Works

Other Resources About Frédéric Y. Bois

What Schools Are Affiliated With Frédéric Y. Bois?

Frédéric Y. Bois's AcademicInfluence.com Rankings